Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Vladimir J N Bykov

Showing results (1-10 of 32) with videos related to

Pageof 4
Sort By:
Annals of Medicine|December 3, 2003
Novel cancer therapy by reactivation of the p53 apoptosis pathwayVladimir J N Bykov, Klas G Wiman
FEBS Letters|April 29, 2014
Mutant p53 reactivation by small molecules makes its way to the clinicVladimir J N Bykov, Klas G Wiman
Biochemical and Biophysical Research Communications|May 25, 2010
The p53 tumor suppressor: a master regulator of diverse cellular processes and therapeutic target in cancerMarianne Farnebo, Vladimir J N Bykov, Klas G Wiman
Cell Chemical Biology|July 31, 2018
Role of Thiol Reactivity for Targeting Mutant p53Qiang Zhang, Jan Bergman, Klas G Wiman, et al.
Carcinogenesis|January 1, 2003
Mutant p53-dependent growth suppression distinguishes PRIMA-1 from known anticancer drugs: a statistical analysis of information in the National Cancer Institute databaseVladimir J N Bykov, Natalia Issaeva, Galina Selivanova, et al.
Journal of Molecular Cell Biology|March 21, 2019
p53 as a hub in cellular redox regulation and therapeutic target in cancerSofi E Eriksson, Sophia Ceder, Vladimir J N Bykov, et al.
Plos One|November 2, 2023
Pharmacological induction of translational readthrough of nonsense mutations in the retinoblastoma (RB1) geneMireia Palomar-Siles, Viktor Yurevych, Vladimir J N Bykov, et al.
Nature Reviews. Cancer|December 16, 2017
Targeting mutant p53 for efficient cancer therapyVladimir J N Bykov, Sofi E Eriksson, Julie Bianchi, et al.
Journal of Glaucoma|August 17, 2018
Needling With 5-Fluorouracil (5-FU) After XEN Gel Stent Implantation: 6-Month OutcomesThorsteinn S Arnljots, Rafael Kasina, Vladimir J N Bykov, et al.
Cell Death & Disease|April 20, 2018
APR-246 reactivates mutant p53 by targeting cysteines 124 and 277Qiang Zhang, Vladimir J N Bykov, Klas G Wiman, et al.
Pageof 4

Showing results (1-10 of 32) with videos related to

Sort By:
Pageof 4
Annals of Medicine|December 3, 2003
Novel cancer therapy by reactivation of the p53 apoptosis pathwayVladimir J N Bykov, Klas G Wiman
FEBS Letters|April 29, 2014
Mutant p53 reactivation by small molecules makes its way to the clinicVladimir J N Bykov, Klas G Wiman
Biochemical and Biophysical Research Communications|May 25, 2010
The p53 tumor suppressor: a master regulator of diverse cellular processes and therapeutic target in cancerMarianne Farnebo, Vladimir J N Bykov, Klas G Wiman
Cell Chemical Biology|July 31, 2018
Role of Thiol Reactivity for Targeting Mutant p53Qiang Zhang, Jan Bergman, Klas G Wiman, et al.
Carcinogenesis|January 1, 2003
Mutant p53-dependent growth suppression distinguishes PRIMA-1 from known anticancer drugs: a statistical analysis of information in the National Cancer Institute databaseVladimir J N Bykov, Natalia Issaeva, Galina Selivanova, et al.
Journal of Molecular Cell Biology|March 21, 2019
p53 as a hub in cellular redox regulation and therapeutic target in cancerSofi E Eriksson, Sophia Ceder, Vladimir J N Bykov, et al.
Plos One|November 2, 2023
Pharmacological induction of translational readthrough of nonsense mutations in the retinoblastoma (RB1) geneMireia Palomar-Siles, Viktor Yurevych, Vladimir J N Bykov, et al.
Nature Reviews. Cancer|December 16, 2017
Targeting mutant p53 for efficient cancer therapyVladimir J N Bykov, Sofi E Eriksson, Julie Bianchi, et al.
Journal of Glaucoma|August 17, 2018
Needling With 5-Fluorouracil (5-FU) After XEN Gel Stent Implantation: 6-Month OutcomesThorsteinn S Arnljots, Rafael Kasina, Vladimir J N Bykov, et al.
Cell Death & Disease|April 20, 2018
APR-246 reactivates mutant p53 by targeting cysteines 124 and 277Qiang Zhang, Vladimir J N Bykov, Klas G Wiman, et al.
Pageof 4